Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction

Modern Pathology

Volumn 16, Issue 12, 2003, Pages 1248-1256

  Morowitz, Michael ^a   Shusterman, Suzanne ^a   Mosse, Yael ^a   Hii, George ^a   Winter, Cynthia L ^a   Khazi, Deepa ^a   Wang, Qun ^a   King, Rebecca ^a   Maris, John M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Chromosome 17; Fluorescence in situ hybridization; Genetics; MYCN; Neuroblastoma; Quantitative PCR; Unbalanced gain

Indexed keywords

ARTICLE; CHROMOSOME 17Q; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MYCN GENE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0346992283     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000097364.64566.81     Document Type: Article

References (28)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott; 2002. p. 895-938.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
3. Brodeur G, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224: 1121-4.
4. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
5. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. The International Neuroblastoma Pathology Classification (Shimada) System. Cancer 1999;86:364-72.
6. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol 1991;9:581-91.
7. Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, et al. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10:103-14.
8. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-21.
9. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
10. Lastowska M, Roberts P, Pearson AD, Lewis I, Wolstenholme J, Bown N. Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer 1997;19:143-9.
11. Meddeb M, Danglot G, Chudoba I, Venuat AM, Benard J, Avet-Loiseau H, et al. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer 1996;17:156-65.
12. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994;55:334-40.
13. McConville CM, Dyer S, Rees SA, Luttikhuis ME, McMullan DJ, Vickers SJ, et al. Molecular cytogenetic characterization of two non-MYCN amplified neuroblastoma cell lines with complex t(11;17). Cancer Genet Cytogenet 2001;130:133-40.
14. Stark B, Jeison M, Bar-Am I, Glaser-Gabay L, Mardoukh J, Luria D, et al. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping. Genes Chromosomes Cancer 2002;34:313-24.
15. Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
16. Mathew P, Valentine MB, Bowman LC, Rowe ST, Nash MB, Valentine VA, et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 2001;3:105-9.
17. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997;150:81-9.
18. Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001;36:11-3.
19. Lastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, et al. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002;34:428-36.
20. Trakhtenbrot L, Cohen N, Betts DR, Niggli FK, Amariglio N, Brok-Simoni F, et al. Interphase fluorescence in situ hybridization detection of chromosome 17 and 17q region gains in neuroblastoma: are they secondary events? Cancer Genet Cytogenet 2002;137:95-101.
21. Applied Biosystems. ABI PRISM 7700 Sequence Detection System User Guide. In: User Bulletin #2: Applied Biosystems.
22. Abel F, Ejeskar K, Kogner P, Martinsson T. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 1999;81:1402-9.
23. Lastowska M, Cotterill S, Pearson AD, Roberts P, McGuckin A, Lewis I, et al. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur J Cancer 1997;33:1627-33.
24. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001;19:3080-90.
25. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15: 159-66.
26. Cunsolo CL, Bicocchi MP, Petti AR, Tonini GP. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br J Cancer 2000;83:1295-300.
27. Lastowska M, Van Roy N, Bown N, Speleman F, Lunec J, Strachan T, et al. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. Genes Chromosomes Cancer 1998;23:116-22.
28. Ambros IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 1996;334:1505-11.